Clearbridge BioMedics wins Asian Entrepreneurship Award in Japan
Clearbridge BioMedics has won the 2012 Asian Entrepreneurship awards, which was held from 9-11 May 2012 in Kashiwanoha, Chiba Prefecture in Japan. A total of 18 start-up companies, from 12 Asian countries presented their business plans at this inaugural business competition. Clearbridge BioMedics impressed the judges with its ClearCell™ System. This is a cell-based invitro diagnostic device that can isolate and retrieve intact and viable circulating tumour cells from blood. Clearbridge BioMedics, which was the only Singaporean company to participate, took home the 3 million yen (approximately SGD 47,000) prize money along with three years of free tenancy at the Tokatsu Techno Plaza in Chiba Prefecture. Clearbridge BioMedics is a spin-off company from the Faculty of Engineering, National University of Singapore.
“We are delighted and honoured to win the inaugural Asian Entrepreneurship Awards. Participating in this event was a great experience for us. We were able to network and present to an audience, including venture capitalists, entrepreneurs and potential partners. Japan is a very important market for us, winning this award will be a launch pad for us to bring the technology there.” said Dr Andrew Wu, Project Director Clearbridge BioMedics.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.